(Q33998617)

30 July 2017

title

CNS manifestations of Fabry's disease (English)

1 reference

30 July 2017

1 reference

Andreas Fellgiebel

1

1 reference

30 July 2017

Matthias J Müller

series ordinal

2

1 reference

30 July 2017

Lionel Ginsberg

series ordinal

3

1 reference

30 July 2017

publication date

1 September 2006

1 reference

30 July 2017

1 reference

30 July 2017

volume

5

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

791-795

1 reference

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Cerebrovascular complications of Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Magnetic resonance imaging changes in Fabry disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

A 32-year-old man with relapsing-progressive brainstem symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Gene action in the X-chromosome of the mouse (Mus musculus L.)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Quantitative analysis of cerebral vasculopathy in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

White matter lesion severity in male and female patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Magnetic resonance image findings in 5 young patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Diffuse structural and metabolic brain changes in Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Radiological evidence of early cerebral microvascular disease in young children with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Pathogenesis of leukoaraiosis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

High total cerebral blood flow is associated with a decrease of white matter lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Effect of genetic modifiers on cerebral lesions in Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Fabry disease: immunocytochemical characterization of neuronal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

A prospective study of cerebral ischemia in the young. Analysis of pathogenic determinants. The National Research Council Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Ischemic stroke in young adults. Experience in 329 patients enrolled in the Iowa Registry of stroke in young adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Endothelial markers and homocysteine in patients with classic Fabry disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Fabry disease: overall effects of agalsidase alfa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970548-8

7 January 2021

10.1016/S1474-4422(06)70548-8

Identifiers

DOI

1 reference

30 July 2017

1 reference